Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NeoGenomics Bolsters Liquid Diagnostics Portfolio By Acquiring Inivata

Executive Summary

Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.

You may also be interested in...



Minute Insight: Inivata's RaDaR Assay Study Yields Encouraging Results

RaDaR, a test for head and neck squamous cell carcinoma, demonstrated high efficacy in a new study.

Inivata Continues Trials Of Its Liquid Biopsy Platform

The partnership with the Princess Margaret Cancer Center will support two studies of liquid biopsy testing for lung cancer.

Q2 Dealmaking Statistics: Medtech And Diagnostics M&A And Alliance Activity, April-June 2021

During the second quarter of 2021, device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT143884

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel